Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIRANDA: Tozorakimab in COPD with history of exacerbations
jRCT2041230113Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Tozorakimab with Placebo (2 arms). Primary endpoint: Annualized rate of moderate to severe COPD exacerbations in former smokers. Started Jan 2024; status: active, not recruiting.
02
Drugs
tozorakimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on jRCT2041230113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041230113.